高级检索
当前位置: 首页 > 详情页

Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China [2]Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430077, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Peoples R China [4]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China
出处:
ISSN:

关键词: Prodrug Nano-Vaccine Chemo-Immunotherapy Melanoma Erythrocyte

摘要:
There are plenty of evidences to show that combining of chemotherapy and immunotherapy should be a very potent anti-cancer therapeutic method. In this research, we evaluated the anti-tumor activity of doxorubicin prodrug combined with erythrocyte membrane-enveloped polymer nano-vaccine against tumor in vitro and in vivo. We also analyzed the immune cell populations to investigate the effect in the tumor microenvironment and explored the inhibitory of lung metastasis. Our study showed that chemo-immunotherapy could inhibit the growth of melanoma tumor in mice. This combination approach promoted a stronger immune response by upregulating the expression of dendritic cells and cytotoxic T cells in lymph nodes and increased the secretion of cytokines. It also restricted the immunosuppressive environment through inhibiting expression of regulatory T cells. It suggested that combination of prodrug and nano-vaccine achieved better anti-tumor effect than monotherapy, which should be widely valued and further studied to establish in a more economical and efficient way, expected to apply in the future clinical practice of cancer treatment.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 2 区 药学
JCR分区:
出版当年[2018]版:
Q1 PHARMACOLOGY & PHARMACY Q2 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Peoples R China
通讯作者:
通讯机构: [2]Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430077, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)